Authors
Latest:
FDA Grants Alzheimer Biomarker Test Breakthrough StatusThe FDA has granted a Breakthrough Device Designation to the Elecsys beta-Amyloid (1-42) and Elecsys Phospho-Tau (181P) cerebrospinal fluid assays, which can be used in the diagnosis of Alzheimer disease.
Latest:
Paula E. Voinescu, MD, PhD: Seizure Frequency in Pregnancy, PostpartumThe attending neurologist at Brigham and Women's Hospital spoke about how seizure frequency during pregnancy and postpartum varies by epilepsy type.
Latest:
Characteristics of and Prevention Methods for Cerebral Palsy: Bhooma Aravamuthan, MD, DPhilThe assistant professor of pediatric neurology at Washington University in St. Louis provided an overview of cerebral palsy and ways to reduce the risk of developing the condition. [WATCH TIME: 3 minutes]
Latest:
Advancing Alzheimer Treatment Through Gamma Oscillation Stimulation: Ralph Kern, MD, MHScThe chief medical officer at Cognito Therapeutics talked about a medical device designed to slow cognitive decline in patients with Alzheimer disease through gamma frequency brain stimulation. [WATCH TIME: 6 minutes]
Latest:
Highlights on Exploring Advances in Headache Medicine from AHS Scottsdale 2024: MaryAnn Mays, MDThe neurologist in the Headache Center at Cleveland Clinic shared her post perspective on the 2024 AHS Scottsdale meeting which highlighted advancements in headache medicine and the growing impact of the field on patient care. [WATCH TIME: 5 minutes]
Latest:
Changes in Themes Across Neurology Over the Years: Rebecca Gottesman, MD, PhD, FANA; Frances E. Jensen, MD, FACPThe president of the ANA and the chair of the annual meeting programming committee provided commentary on the advances in neurology and the shift in how clinicians approach and treat diseases once thought to be fatal. [WATCH TIME: 6 minutes]
Latest:
Greater Insights into Seizure Causes With Epilepsy Genetic Testing in Adults: Yi Li, MD, PhDThe clinical assistant professor of neurology at Stanford University talked about findings from a study on genetic testing in adults with epilepsy and the importance of access to genetic testing for this patient population. [WATCH TIME: 7 minutes]
Latest:
Developing Cell Therapy for Progressive MS: Jakob Dupont, MD, MAThe head of global research and executive vice president of Atara Biotherapeutics discussed the upcoming study evaluating ATA188.
Latest:
The Clinical Pearls for Diagnosing and Treating NMOSD: Brian G. Weinshenker, MD, FRCPThe professor of neurology at the University of Virginia talked about the improvement and areas of unmet need in the diagnosis and treatment for neuromyelitis optica spectrum disorder. [WATCH TIME: 6 minutes]
Latest:
Unanswered Questions, Challenges in Epilepsy Diets: Robyn Blackford, RD, LDNThe registered dietitian at Ann & Robert H. Lurie Children’s Hospital discussed the unknowns in terms of managing and prescribing diets for patients with epilepsy. [WATCH TIME 3 minutes]
Latest:
Elixirgen Therapeutics’ Bobcat mRNA Therapeutic for Duchenne Muscular Dystrophy: Aki KoThe chief executive officer at Elixirgen Therapeutics discussed the company’s mRNA as a promising therapeutic avenue for Duchenne muscular dystrophy. [WATCH TIME: 6 minutes]
Latest:
State of Multiple Sclerosis Research and Understanding of the Impact of Age and Sex: Nancy Sicotte, MDThe chair of the Department of Neurology at Cedars Sinai Medical Center discussed the prominent topics of research in multiple sclerosis and the need to learn more about age and sex. [WATCH TIME: 5 minutes]
Latest:
Diving Into the Potential of Monoclonal Antibodies for Alzheimer Disease Treatment: Gayatri Devi, MDThe clinical professor of neurology at Lenox Hill Hospital/Northwell Health talked about her experience with monoclonal antibodies for Alzheimer disease treatment as well as the challenges and risks associated with them. [WATCH TIME: 8 minutes]
Latest:
Challenges and Opportunities Bringing Lecanemab to Neurology Community ClinicsA group of experts from The Neuron Clinic shared their experience developing a novel inclusive clinical program to treat patients with early Alzheimer disease using lecanemab.
Latest:
Addressing the Invisible Symptoms of Duchenne Muscular Dystrophy: Mathula Thangarajh, MD, PhDThe assistant professor at Virginia Commonwealth University provided comment on her presentation from AANEM 2023, and the need to raise awareness towards nonneuromuscular symptoms of Duchenne muscular dystrophy. [WATCH TIME: 4 minutes]
Latest:
Ongoing Clinical Trials and the Future of ALSKey opinion leaders review the study design and mechanisms of action for drugs in ongoing clinical trials and consider the future of amyotrophic lateral sclerosis (ALS).
Latest:
The Road to Precision Medicine in Alzheimer Disease Through Biomarkers: Hans J. Moebius, MD, PhDThe chief medical officer at Athira Pharma talked about an exploratory phase 2 trial that showcased the correlation between biomarkers for Alzheimer disease hallmarks and neuroinflammation. [WATCH TIME: 5 minutes]
Latest:
A Team Approach to Asleep Deep Brain StimulationHenry Ford Health System’s investment in advanced DBS technology and its commitment to multidisciplinary care has helped them become a leading treatment center for Parkinson disease and related movement disorders.
Latest:
Next Steps in Expanding, Validating Capabilities of PrimSeq Digital Stroke Rehabilitation Tool: Heidi Schambra, MDThe associate professor in the Department of Rehabilitation Medicine at NYU Langone provided commentary on when the PrimSeq digital tool could see substantial impact on rehabilitation for stroke survivors and other neurological diseases. [WATCH TIME: 4 minutes]
Latest:
Why Trump and Musk's Alliance Could Launch America's Neurotech MoonshotNeal K. Shah, CEO at CareYaya Health Technologies, shared his perspective on how the new administration could unleash innovation in neurotech, reduce regulatory barriers with Elon Musk’s involvement, and accelerate innovations that could improve neurological care for those with Alzheimer and dementia.
Latest:
Practice Pearls for Management of NMOSDExperts in neurology discuss immune tolerance as an alternative strategy and share practice pearls for approaching treatment of NMOSD.
Latest:
Implementing Headache Training in ResidencyDespite a tremendous burden regarding migraine-related disability and expenditure, headache disorders remain underdiagnosed and undertreated, and only a small percentage of patients report satisfaction with the treatment received.
Latest:
AUPN 2022 Women Leaders in NeurologyLaurie Gutmann, MD; Gauri Pawar, MD; and Claire Henchcliffe, MD, discuss their own paths in medicine and observations of other women leaders. [WATCH TIME: 1 hour, 51 minutes]
Latest:
PPD/TFS Fostering Global Awareness in Rare DisordersRare Disease Day raises awareness for rare disorders, highlighting challenges, improving detection, and fostering collaboration for treatment advancements.
Latest:
Roundtable: The Future of Stereotactic and Functional NeurosurgeryTwo experts at Jefferson Health discuss several topics related to advances in neurosurgery, technology, and the future of minimally invasive procedures.
Latest:
Trichloroethylene Exposure and Usage, Environmental Associations in Parkinson Disease: Samuel M. Goldman, MD, MPHThe clinical professor in the department of neurology at the University of California, San Francisco, emphasized the need to restrict trichloroethylene availability and the challenges in studying environmental factors associated with Parkinson disease. [WATCH TIME: 4 minutes]
Latest:
AUPN Leadership Minute Episode 31: Recruitment and Retention of FacultyEpisode 31 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the VHA and Albany Medical College; and Adam Newsom, of Merritt Hawkins. [WATCH TIME: 5 minutes]
Latest:
Therapeutic Potential of Transcranial Direct Current Stimulation in Primary Progressive Aphasia: Leigh Charvet, PhDThe professor of neurology at the NYU Grossman School of Medicine provided commentary on a study that demonstrated the benefits of using tDCS along with sleep language training to promote naming in primary progressive aphasia. [WATCH TIME: 5 minutes]
Latest:
The State of Coma Care: A Call for ActionOur moon shot to curing coma will take everyone. We all need to work together toward the grand challenge of awakening hope.
Latest:
Overviewing Phase 2 SYNAPSE-SMA Trial of NMD670 for Spinal Muscular Atrophy: Jorge Quiroz, MD, MBAThe chief medical officer of NMD Pharma provided perspective on a newly launched phase 2 study assessing NMD670, a first-in-class neuromuscular transmission enhancer, in patients with spinal muscular atrophy type 3. [WATCH TIME: 5 minutes]
